Chondrocalcinosis: Causes, Symptoms, and Treatment

Chondrocalcinosis is the buildup of calcium pyrophosphate (CPP) crystals inside joint cartilage, visible on X-rays as white, chalky deposits and capable of triggering painful arthritis flares that closely mimic gout or joint infections. The condition falls under a broader umbrella called calcium pyrophosphate deposition (CPPD) disease, and it becomes increasingly common with age, affecting a substantial share of people over 60. While there is no treatment that dissolves the crystals once they form, the inflammation and pain they cause can be managed effectively in most cases.

How the Crystals Form

The crystals behind chondrocalcinosis are made of calcium pyrophosphate dihydrate. They form when inorganic pyrophosphate, a byproduct of normal energy metabolism, combines with calcium ions inside cartilage. An enzyme called ectonucleotide pyrophosphatase/phosphodiesterase-1 cleaves ATP and releases pyrophosphate into the joint space; when pyrophosphate concentrations climb high enough, crystals start to precipitate.¹ Magnesium normally helps keep pyrophosphate levels in check by boosting an enzyme that clears it, so when magnesium is low, crystal formation accelerates. This is why metabolic conditions that alter calcium, phosphate, or magnesium balance in the body are so tightly linked to the disease.

Metabolic and Medical Causes

Most chondrocalcinosis in older adults is considered idiopathic, meaning no single cause is identified. But several metabolic conditions reliably raise the risk. The strongest associations are with hyperparathyroidism (overactive parathyroid glands, which elevate calcium), hypomagnesemia (low magnesium), and hypophosphatasia (a rare enzyme deficiency that increases pyrophosphate).² Hemochromatosis, a condition in which the body absorbs too much iron, stands out because it is linked not only to crystal deposits but also to chronic structural joint damage, going beyond just acute flares.²

Hypomagnesemia deserves special attention because it can be caused by medications (certain diuretics, proton-pump inhibitors) or by inherited kidney conditions like Gitelman syndrome.³ When chondrocalcinosis shows up in someone younger than 55, or when it appears in multiple joints at once, clinicians are generally advised to screen for these underlying metabolic disorders. Correcting the metabolic problem won’t dissolve crystals already deposited, but it can slow further accumulation.

Genetic Forms

A minority of cases run in families, sometimes striking people decades earlier than the typical age-related pattern. The best-studied genetic culprit is the ANKH gene, which encodes a protein that transports pyrophosphate out of cells and into the joint space. Mutations in ANKH increase that transport activity, flooding the cartilage environment with excess pyrophosphate and promoting crystal formation.⁴ These familial forms tend to be autosomal dominant, meaning inheriting just one copy of the mutation from either parent is enough to cause disease.⁵

Familial chondrocalcinosis can appear as early as the third or fourth decade of life. It often involves more joints than the sporadic form and can progress more aggressively. The identification of ANKH mutations has been an important piece of the puzzle, but the causes of the far more common sporadic form remain poorly understood. The suspicion is that aging-related changes in cartilage, combined with subtle metabolic shifts, create conditions favorable for crystal growth even without a single identifiable trigger.

Which Joints Are Affected

The knee is the classic site, and it is where chondrocalcinosis is most often detected on routine X-rays. Within the knee, the fibrocartilage of the meniscus is affected far more often than the hyaline cartilage that lines the bone ends. One study of knee imaging found fibrocartilage involvement in roughly 90% of affected knees, compared to about 55% for hyaline cartilage, and isolated fibrocartilage deposits were much more common than isolated hyaline cartilage deposits.⁶ This preference for fibrocartilage is a useful diagnostic clue, since it gives chondrocalcinosis a distinctive appearance on X-rays: fine, linear calcifications within the meniscus, paralleling the bone surfaces.

But the condition is far from knee-exclusive. The wrists, hips, shoulders, and the triangular fibrocartilage of the wrist are all common sites. The finding that chondrocalcinosis frequently occurs at multiple joints simultaneously is consistent across studies. A person found to have calcifications in one knee often has them elsewhere too, though they may not cause symptoms at every site.

Symptoms and How They Present

Chondrocalcinosis itself, meaning the crystal deposits visible on imaging, can be completely silent. Many people have calcified cartilage without ever knowing it. The condition becomes clinically important when those crystals trigger inflammation, and the resulting disease, CPPD, presents in several overlapping patterns.

The most dramatic is acute CPP crystal arthritis, historically called “pseudogout.” A joint, often the knee or wrist, swells rapidly over hours, becomes intensely painful, warm, and red. The flare looks almost identical to gout or to a bacterial joint infection, which makes it notoriously tricky to diagnose on clinical appearance alone.⁷ Fever can accompany the attack, adding to the confusion with infection.

A chronic form also exists, sometimes resembling rheumatoid arthritis with ongoing low-grade joint inflammation in multiple joints, or mimicking osteoarthritis with gradual cartilage loss and stiffness. This chronic pattern can be hard to distinguish from ordinary wear-and-tear arthritis, and the two frequently coexist in the same person. Because CPPD most commonly affects older adults who already have osteoarthritis, untangling which condition is driving their pain can be a genuine clinical challenge.⁷

Crowned Dens Syndrome

One of the more unusual and underrecognized presentations involves the spine. Crowned dens syndrome occurs when CPP crystals deposit around the odontoid process, the peg-shaped projection of the second cervical vertebra in the upper neck. It causes sudden, severe neck pain, often with fever and a stiff neck, and it is frequently misdiagnosed as meningitis, stroke, or giant cell arteritis because the symptoms overlap so closely.⁸

A systematic review of nearly 200 reported cases found that neck pain was present in about 97% of patients, and inflammatory blood markers were elevated in the vast majority. CT scans of the neck caught the characteristic calcifications around the dens in about 97% of cases, far outperforming both MRI and plain X-rays for detection.⁹ Despite these reliable imaging findings, the condition often goes unrecognized. In one hospital-based study, only about a third of patients with the characteristic calcifications around the dens were actually diagnosed with crowned dens syndrome by their treating physicians, while the rest were either not evaluated by a rheumatologist or had the finding missed entirely.¹⁰ The good news is that it generally responds well to anti-inflammatory treatment, with improvement in about 97% of cases, and meningitis was the most frequent misdiagnosis at about 21%.⁹

How Chondrocalcinosis Is Diagnosed

The gold standard for confirming CPPD disease is identifying the crystals themselves. When a joint is swollen and fluid can be aspirated with a needle, viewing that fluid under a polarized-light microscope reveals the characteristic rhomboid-shaped, weakly positively birefringent crystals. This examination is also critical for ruling out gout (whose crystals look different under the microscope) and infection (where bacteria or a positive culture would be found).¹¹

That said, crystal identification in joint fluid is not always straightforward. One study from a tertiary care center found CPP crystals in only about 55% of synovial fluid samples from patients ultimately diagnosed with CPPD. Interestingly, CPP crystals also showed up in about 43% of samples from patients with osteoarthritis, underlining how commonly the two conditions overlap.¹² This means a negative crystal analysis does not completely rule out CPPD, and imaging plays an important supporting role.

Conventional X-rays remain the most accessible imaging tool. They can show the linear calcifications within cartilage that define chondrocalcinosis, but they have limited sensitivity, particularly for subtle deposits. One study comparing imaging modalities found that conventional X-rays detected crystals with a sensitivity of only about 44%, while dual-energy CT (DECT) achieved roughly 78% sensitivity with high specificity around 94%.¹³ Ultrasound is another option and has shown high sensitivity in pilot data, with particular strength in identifying crystal deposits in superficial joints like the knee and wrist.¹⁴ In practice, a combination of clinical history, joint fluid analysis when available, and imaging usually gives the clearest diagnostic picture.

Treating Acute Flares

When an acute attack of CPP crystal arthritis hits, the immediate goal is to shut down the inflammatory response as quickly as possible. The three mainstays are NSAIDs, colchicine, and corticosteroids.¹⁵ The choice among them depends largely on the patient’s other medical conditions. NSAIDs work well for people with healthy kidneys and no significant cardiovascular risk, but many CPPD patients are elderly and have comorbidities that make NSAIDs risky. Colchicine is most effective when started early in a flare. Corticosteroids, either taken orally, injected into the affected joint, or given by intramuscular injection, are often the safest option for older patients who cannot tolerate the alternatives.

Joint aspiration itself, even before any medication is given, can provide significant relief by reducing pressure within the swollen joint. When a joint is aspirated and corticosteroid is injected directly into it, many patients experience rapid improvement within a day or two.

When Standard Treatments Fail

Some patients have flares that resist the usual first-line drugs, or they have medical conditions like kidney failure that limit what they can safely take. In these refractory cases, anakinra, an interleukin-1 receptor antagonist originally developed for rheumatoid arthritis, has shown promise. A case series of five patients with CPP crystal arthritis unresponsive to conventional therapy found that four showed rapid clinical improvement within an average of three days, with substantial drops in both pain scores and inflammatory markers.¹⁶ In patients on dialysis for end-stage kidney disease, where NSAIDs and colchicine are essentially off the table, anakinra has allowed both rapid resolution of flares and complete withdrawal of long-term steroids.¹⁷

Anakinra is not a cure and is not yet widely studied in large randomized trials for CPPD, but for patients with limited options, it represents one of the few targeted therapies available. This is an area of active research interest.

The Chronic Management Problem

Unlike gout, where medications like allopurinol can lower uric acid and gradually dissolve crystals, there is no approved drug that reduces the CPP crystal burden once it has built up in cartilage.¹⁸ This is one of the most frustrating aspects of the disease for patients and clinicians alike. Treatment for the chronic forms of CPPD, whether it resembles ongoing inflammatory arthritis or progressive osteoarthritis, is symptom-focused. Low-dose colchicine is sometimes used as a prophylactic measure to reduce the frequency of flares, and low-dose NSAIDs or hydroxychloroquine have been tried for chronic inflammatory symptoms, though the evidence base for all of these is thin.

Physical therapy plays a role in maintaining joint function and managing pain over the long term. A case study documented the use of targeted exercises addressing the peripheral source of pain, combined with pain-relieving modalities, for a patient with pseudogout.¹⁹ While evidence from large trials on physical therapy for CPPD specifically is lacking, the general principles of joint protection, range-of-motion exercises, and strengthening apply as they would for osteoarthritis.

The Overlap with Septic Arthritis

One of the genuine dangers of chondrocalcinosis is that when it flares, it can look so much like a joint infection that distinguishing the two becomes a clinical emergency. A hot, swollen, red joint with fever raises the specter of septic arthritis, which requires urgent antibiotics and sometimes surgical washout to prevent permanent joint destruction. Pseudogout can produce exactly this picture. Making things worse, the two conditions can coexist: crystal-induced inflammation and bacterial infection can both be present in the same joint at the same time.¹¹

This is why clinicians generally aspirate the joint when infection is a possibility, even if CPPD is suspected. Looking at the fluid under a microscope and sending it for bacterial culture can settle the question. Treating an acute CPPD flare with anti-inflammatories while an underlying infection is missed could have serious consequences, so the threshold for joint aspiration in ambiguous cases is deliberately low.

Impact on Daily Life

The experience of living with CPPD is often underappreciated. Qualitative research from the OMERACT CPPD Working Group found that acute flares caused temporary but profound disability for most patients, disrupting their ability to perform household tasks, care for themselves, exercise, socialize, work, and drive.²⁰ Patients with the chronic inflammatory form or with CPPD coexisting alongside osteoarthritis described longer-term limitations and adverse effects on psychological wellbeing.²⁰

Overall function and the ability to complete daily tasks were the most commonly identified outcome domains across patients, caregivers, and healthcare professionals in a separate analysis from the same working group.²¹ Caregivers, too, reported significant effects on their own lives, particularly when patients lost the ability to drive or manage tasks independently. The unpredictable timing of flares adds a layer of anxiety: patients described not knowing when the next episode would strike, making it hard to plan travel, social commitments, or even a full workday.

When Chondrocalcinosis Appears in Younger Adults

While chondrocalcinosis is overwhelmingly a disease of people over 60, it occasionally shows up in younger adults. When it does, the index of suspicion for an underlying cause should be high. Familial CPPD linked to ANKH mutations can present in the thirties or forties.⁵ Metabolic screening in younger patients typically includes parathyroid hormone, calcium, magnesium, ferritin and transferrin saturation (for hemochromatosis), and alkaline phosphatase levels. Identifying a treatable metabolic condition early can make a meaningful difference in slowing progression, even though crystals already deposited will stay put.

Younger patients with familial forms tend to have more joints involved and may face a more progressive course. There is no formal guideline specifying an exact age cutoff for mandatory screening, but most rheumatology practice recommendations suggest investigating when CPPD appears before age 55 or when it involves atypical joint distributions.

Destructive Arthropathy

In rare cases, chondrocalcinosis is associated with a severely destructive form of arthropathy that resembles the joint breakdown seen in neuropathic (Charcot) joints. This pseudo-neuropathic pattern involves dramatic bone and cartilage loss, joint instability, and large effusions, and it can progress even in the absence of frequent acute flares.²² The shoulders and knees are the joints most commonly affected by this severe pattern. It is uncommon enough that many clinicians may only encounter it a handful of times in their career, but for those affected, it can lead to substantial disability and may ultimately require joint replacement surgery. The mechanisms driving this destructive subset remain poorly understood, and there is no reliable way to predict which patients with chondrocalcinosis will develop it.

1
The Lancet Rheumatology. Chondrocalcinosis: Causes, Symptoms, and Treatment – Section: Pathophysiology of CPPD disease
2
Seminars in Arthritis and Rheumatism. Diseases associated with calcium pyrophosphate deposition disease
3
PubMed. Chondrocalcinosis secondary to hypomagnesemia in Gitelman’s syndrome
4
PubMed. The ANKH gene and familial calcium pyrophosphate dihydrate deposition disease
5
Nature Reviews Rheumatology. Pathophysiology of articular chondrocalcinosis—role of ANKH
6
PubMed Central. Chondrocalcinosis is common in the absence of knee involvement
7
PubMed Central. Diagnosis and Treatment of Calcium Pyrophosphate Deposition (CPPD) Disease: A Review
8
PubMed Central. Crowned Dens Syndrome: A Challenging Diagnosis in Older Adults Presenting With Acute Neck Pain
9
PubMed. Clinical features and diagnostic challenges in crowned dens syndrome: a systematic review and meta-analysis
10
PubMed. Cervical CT-Dependent Diagnosis of Crowned Dens Syndrome in Calcium Pyrophosphate Dihydrate Crystal Deposition Disease
11
PubMed Central. Pseudogout Masquerading as Septic Arthritis in a Patient With Rheumatoid Arthritis
12
PubMed. Synovial fluid analysis for the enhanced clinical diagnosis of crystal arthropathies in a tertiary care institution
13
PubMed Central. Detection of calcium pyrophosphate dihydrate crystals in knee meniscus by dual-energy computed tomography
14
Arthritis & Rheumatology. Sensitivity of Dual-Energy CT, Ultrasound, and X-Ray for Pseudogout: A Pilot Study
15
Frontiers in Medicine. Recent advances in the therapeutic management of calcium pyrophosphate deposition disease
16
PubMed. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis
17
PubMed Central. Anakinra for Refractory Pseudogout in Patients with End-stage Renal Disease on Haemodialysis
18
PubMed Central. Treatment and management of pseudogout: insights for the clinician
19
JOSPT Cases. A Mechanistic-Based Approach to the Physical Therapy Management for a Patient With the Diagnosis of Pseudogout: A Case Study
20
PubMed Central. Experience and impact of crystal pyrophosphate deposition (CPPD) from a patient and caregiver perspective: a qualitative exploration from the OMERACT CPPD Working Group
21
PubMed Central. Outcome domains reported by patients, caregivers, healthcare professionals and stakeholders for calcium pyrophosphate deposition (CPPD)
22
PubMed Central. Destructive arthropathy in chondrocalcinosis articularis